Quidel Corporation (Quidel) board has appointed Douglas C. Bryant as president and chief executive officer (CEO) of the company, effective, February 2, 2009. In his most recent endeavor, Bryant served as executive vice president and chief operating officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations.

From 1983 to 2007, Bryant held various worldwide commercial operations roles with Abbott Laboratories including: vice president of Abbott Vascular for Asia/Japan, vice president of Abbott Molecular Global Commercial Operations and vice president of Abbott Diagnostics Global Commercial Operations. Earlier in his time with Abbott, he was vice president of Diagnostic Operations in Europe, the Middle East and Africa, and vice president of Diagnostic Operations Asia Pacific. He holds a B.A. in Economics from the University of California at Davis.

Announcing the appointment, Mark A. Pulido, chairman of the Quidel board, said, “Doug brings a depth of experience and is a highly respected leader in the worldwide diagnostics industry. Doug’s leadership will enable us to accelerate the momentum built over the last several years as we increase market share of our leading products as well as sharpen our focus on new product and technology opportunities.”

“It’s an exciting time to be joining Quidel, with the company well positioned for continued growth,” said Bryant. “I especially look forward to advancing the development and commercialization of the next generation of products and technologies.”

Caren Mason will continue in her current role as president and chief executive officer until March 1, 2009, when. Bryant’s appointment as president and chief executive officer becomes effective. To facilitate the transition in leadership, Mason will serve as a special advisor until her planned retirement on June 1, 2009.